Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Higher-dose ocrelizumab versus approved-dose ocrelizumab in relapsing multiple sclerosis
2020-000893-69Phase 3Active
- Sponsor
- Roche
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ocrelizumab in multiple sclerosis (MS) (2 arms), sponsored by Roche. Primary endpoint: Composite confirmed disability progression sustained for at least 12 weeks. Started Jul 2020; status: active.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2020-000893-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000893-69.